Stockreport

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration [TheStreet.com]

Scinai Immunotherapeutics Ltd. - American Depositary Shares  (SCNI) 
PDF JERUSALEM April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and [Read more]